Covalon Technologies (CVE:COV) Stock Price Up 2.2%

Covalon Technologies Ltd. (CVE:COV)’s share price shot up 2.2% during mid-day trading on Thursday . The company traded as high as C$2.35 and last traded at C$2.30. 13,033 shares were traded during trading, an increase of 17% from the average session volume of 11,148 shares. The stock had previously closed at C$2.25.

Covalon Technologies Trading Down 3.9 %

The company has a debt-to-equity ratio of 7.79, a current ratio of 4.81 and a quick ratio of 6.45. The business’s 50 day moving average price is C$2.05 and its 200-day moving average price is C$1.49. The firm has a market capitalization of C$54.52 million, a price-to-earnings ratio of -11.63 and a beta of 0.52.

Covalon Technologies (CVE:COV) last issued its quarterly earnings results on Wednesday, May 29th. The company reported C$0.06 earnings per share (EPS) for the quarter. Covalon Technologies had a negative net margin of 19.67% and a negative return on equity of 23.98%. The business had revenue of C$8.41 million for the quarter. Equities analysts forecast that Covalon Technologies Ltd. will post 0.3 EPS for the current fiscal year.

About Covalon Technologies

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company's platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity.